Reverse transcriptase polymerase chain reaction (RT-PCR) was applied to evaluate the frequency of tumour cells in PBPC products from 15 high risk Ewing tumour (ET) patients who were treated according to EICESS 92 with high-dose chemotherapy (HDC) and stem cell rescue. Initial tumour cell contamination of the bone marrow (BM) detected by light microscopy was found in five and by RT-PCR in eight cases. RT-PCR was performed on each PBPC sample repeatedly at a sensitivity comparable to 20-100 highly EWS-Fli1 expressing tumour cells per 10 ml of fresh blood. Irrespective of the extent of BM involvement at diagnosis, all BM samples obtained before harvest were RT-PCR negative. Among 12 of 35 analysed apheresis products with single positive RT-PCR results only one sample tested reproducibly positive for tumour cell contamination in independent determinations. These preliminary data suggest that tumour cell contamination of PBPC is rarely found in patients with ET. Keywords: Ewing tumour; minimal residual disease; apheresis products: RT-PCR; EWS-FLI1 Current multimodal therapy may be curative for approximately 70% of patients with localised Ewing tumours (ET). However, for patients with metastatic disease at diagnosis and for about one-third of patients with localised disease, prognosis remains poor, due to relapse after first-line treatment.
Current multimodal therapy may be curative for approximately 70% of patients with localised Ewing tumours (ET). However, for patients with metastatic disease at diagnosis and for about one-third of patients with localised disease, prognosis remains poor, due to relapse after first-line treatment. [1] [2] [3] [4] Thus, minimal numbers of potentially metastatic tumour cells are postulated to be present in the circulation of almost every patient, even in the absence of clinically overt disseminated disease at diagnosis.
For solid tumours, viable tumour cells in the peripheral blood have been demonstrated in patients with neuroblastoma 5 and breast cancer, 6 and transiently in melanoma patients. 7 Since these circulating tumour cells retained their clonogenic potential they may contribute to relapse after autologous reconstitution. Gene marking studies have revealed reinfused tumour cells in the metastases of neuroblastoma and breast cancer patients.
High-dose chemotherapy (HDC) followed by autologous peripheral blood progenitor cell (PBPC) transplantation is effective for the treatment of a number of malignant disorders including metastatic or relapsed ET. 11 Preliminary data from non-paediatric malignancies suggest that patients receiving tumour cell contaminated autografts do worse than patients transplanted with autografts free of detectable minimal residual disease (MRD). 12 Previously, it has been demonstrated for patients with neuroblastoma, that PBPC harvests are less contaminated by tumour cells than bone marrow 13 and different purging methods have been established to reduce the tumour load in stem cell preparations. 8, 14 Little is known about the mobilisation of tumour cells by growth factors. Data from multiple myeloma patients suggest a concomitant mobilisation of myeloma cells with chemotherapy and G-CSF. 15 This observation was not confirmed in patients with breast cancer. 16 Overall, methods for sensitive tumour cell monitoring are warranted to guarantee autograft quality. Based on the presence of unique chimeric transcripts in ET cells the feasibility of reverse transcriptase polymerase chain reaction methodology (RT-PCR) for follow-up of MRD in ET patients has been demonstrated recently by several groups. [17] [18] [19] In addition, we have previously reported on transient mobilisation of RT-PCR detectable numbers of ET cells into the peripheral blood during tumour biopsies and extensive surgical procedures. 20 The targets for RT-PCR result from alternative gene fusions between the EWS gene and the closely related ETS transcription factor genes FLI1, ERG or FEV, in approximately 87%, 10% and less than 1% of tumours, or ETV1 or E1AF in rare cases, respectively. 21 Thus, EWS gene rearrangements can be detected in at least 98% of ET patients.
In the present study we report on the incidence of RT-PCR detectable tumour cell contamination in PBPC samples from patients with localised and metastatic ET.
Materials and methods

Patients
The study cohort comprised 15 patients from a single institution (10 female, five male) between 8 months and 25 years of age (median age 16 years) ( 
Treatment and mobilisation regimen
All patients were treated according to the EICESS 92 protocol, which includes etoposide vincristine, actinomycin D, ifosfamide and doxorubicin as described elsewhere. 20 PBPC mobilisations by cytokine treatment were performed after two to seven (mean four) cycles of chemotherapy in patients without relapse. In patient No. 6, PBPC were mobilised at the end of EICESS 92 protocol because of lack of response (Table 1) . Two relapsed patients (Nos 11, 14) were also mobilised after completion of the EICESS 92 protocol. Cytokine treatment consisted either of G-CSF 10-20 g/kg, GM-CSF 8 g/kg, G-CSF 10 g/kg plus recombinant human erythropoietin 100 IU/kg/day and GM-CSF (5 g/kg) plus recombinant human erythropoietin 100 IU/kg (Table 2) . After each mobilisation, two to four aphereses (median three) were performed. Forty-six apheresis products from 15 patients were available for RT-PCR analysis.
Definition of disease status
Complete response (CR) was defined as absence of disease visible by conventional clinical imaging techniques for at least 4 weeks. In patients with previous bone marrow involvement, bone marrow had to be free of ET cells at sites distant from the primary tumour or known metastases by conventional cytology/histology. Partial remission (PR) was defined as a more than 50% reduction of tumour volume in the sum of lesions by magnetic resonance imaging.
Collection and processing of samples
For initial diagnosis BM samples were aspirated from the pelvis or sternum at two to four independent sites and collected in EDTA before start of chemotherapy and shipped to the laboratory at room temperature. Tumour fragments from the primary tumour site were immediately snap frozen in liquid nitrogen. All samples were received within 24 h. Samples taken from an involved pelvic site were excluded from the analysis because of a possible tumour cell contamination. Two additional trephine bone biopsies were performed and analysed by routine histopathological methods. Pappenheim-stained BM smears were investigated by light microscopy for the presence of small blue round tumour cells. RT-PCR-positive patients had additional BM investigations at definitive surgery or before leukapheresis and finally before HDC. PBPC harvests were performed using a Fenwall CS 3000 plus Omnix (Baxter, Vienna, Austria). PBPC specimens (1-2 ml) were prepared for flow cytometric analysis and clonogenic assays as described elsewhere. 22 For RNA extraction, 0.5-2 ml of BM, peripheral blood and PBPC samples were treated with erythrocyte lysis buffer (155 mm NH 4 Cl, 10 mm KHCO 3 , 0.1 mm EDTA) for 5 min at room temperature, followed by centrifugation for 10 min at 250 g. Between 0.5 and 1.5 ml of the apheresis product containing 18-605 ϫ 10 6 nucleated cells per ml were either processed immediately for RNA extraction or snap frozen in liquid nitrogen for storage. Between 0.5 and 1 g RNA were obtained from 1 ϫ 10 6 nucleated cells in the harvests. Single-tube nested RT-PCR was performed on 1-2 g RNA as described elsewhere. 19 Integrity of total extracted RNA was validated on 1.5% agarose gels and by control amplification of constitutively expressed germline EWS RNA. 19 For sensitivity controls, serial dilutions of the cell line SK-N-MC (AATC HTB10) were used. As a positive control we used RNA from a EWS-Fli1 exon 7/5 fusion expressing cell line, STA-ET-7.2, established at our institution. Thirtyfive PBPC products were analysed for the presence of EWSets chimeric fusion transcripts (Table 2) .
Results
The study cohort was comprised only of patients for whom the exact EWS fusion type was known from the primary tumour. In 15 patients studied, 46 apheresis products were submitted for molecular analysis. Harvest results for CD34-positive cells ranged between 0.12 and 42.2 ϫ 10 6 /kg (median 5.6 ϫ 10 6 /kg) body weight per apheresis procedure (not shown). Eleven samples had to be excluded from the RT-PCR analysis because of poor quality RNA as determined on 1.5% agarose gels. Multiple controls were included in each individual RT-PCR determination. At each time of processing a patient's sample all steps from RNA extraction to PCR were performed in the absence of cells in parallel (cDNA control). A further negative control was included at the time of PCR analysis containing all components but cDNA (PCR control). The ET cell line STA-ET-7.2 served as a positive control. Furthermore, 1 g of RNA extracted from each of three 10 ml samples of fresh blood of a healthy volunteer to which 100, 50 and 20 cells of a defined ET cell line had been added, were analysed in parallel (sensitivity control). We used the cell line SK-N-MC since (1) the EWS-Fli1 RNA content has been previously characterised, 23 and (2) the cell line grows as a monolayer and trypsinisation results in a single-cell suspension that can easily be diluted avoiding formation of cell clumps. Individual patients' RT-PCR results were only included in our study if all negative controls tested negative and all three serial dilutions of the sensitivity control tested positive in parallel. In addition, PCR products obtained from patient's samples were only considered specific if they corresponded to the fusion type identified in the primary tumour (Figure 1 ).
In five of 15 patients ET cells were detected in the initial BM by light microscopy (33%) and by RT-PCR in eight of 14 patients (57%) ( Table 1 ). In contrast, before harvest Figure 1 Representative RT-PCR results for patient No. 9. T, primary tumor sample (expresses EWS-Fli1 exon 7/6 fusion RNA); B1, B2, B3 bone marrow samples taken at diagnosis from three different aspiration sites; B4, bone marrow sample taken before apheresis. A, apheresis product; N1, cDNA control; N2, PCR control; S1, S2, S3 sensitivity controls; P, positive control (cell line STA-ET-7.2 expressing EWS-Fli1 exon 7/5 fusion RNA). The positive result obtained for the apheresis product was reproduced independently four times (Table 2) . no evidence for tumour cells in the BM could be obtained by either method (Table 2) . Eleven PBPC samples from nine patients were RT-PCR positive in a single determination exclusively. Only one apheresis product of patient No. 9 tested positive four times in six independent determinations (Table 2) .
Discussion
During the last few years PCR technology has become a major tool for the analysis of MRD in various malignancies. However, reliability of methods based on the detection of tumor-specific RNA molecules still remains a matter of concern. The sensitivity of MRD detection by RT-PCR is dependent on the copy number of the target RNA in the circulating tumour cells and the number of hematopoietic cells from which RNA is extracted. The probability of inclusion of tumour cells into the sample increases with sample size. RNA extraction results in dilution of the target molecule. Consequently, detectability of the tumour-specific transcript in an aliquot (usually 1 g to 2 g corresponding to 1.5 to 3 million cells) extracted from a large number of cells (10 8 to 10 9 ) is a function of PCR sensitivity. At the same extent of MRD, detectability of the target molecule in RNA extracted from smaller sample sizes is a question of statistical probability that the tumour cell is included in the sample. If so, the target RNA will be present in the sample at less diluted concentrations requiring less sensitivity for detection. However, in the latter case, repeated analyses of several samples would be necessary to obtain a positive RT-PCR result. This may be the situation in the study of apheresis products of ET patients. First, it has been shown, that EWS-Fli1 RNA steady-state levels per cell vary up to at least 20-fold between individual ET cell lines possibly as the result of variable proliferative activity. 23 Currently, nothing is known about the physiological state of circulating primary ET cells. Second, MRD has only rarely been detected in peripheral blood. 17 Thus, tumour cell concentration in apheresis products is likely to be very low or absent. Third, the stability of tumour cells in apheresis products is unknown. Fourth, total cell counts in the apheresis products and consequently the number of cells available for molecular analysis varied in our study cohort. Thus, single RT-PCR positivity observed in 12/35 apheresis products may have resulted from very low levels of MRD. Alternatively, minute cross contamination may also result in sporadic PCR positivity undetectable by the negative controls. Although unlikely under the stringent quality control criteria applied in our study, this possibility can never be excluded completely in a PCR study. In contrast, reproducible RT-PCR positivity, as observed in our study in a single apheresis product, indicates reliably the presence of tumour cell-specific RNA at a threshold defined by our sensitivity controls. The cell line SK-N-MC which has been used in serial dilutions of 100, 50 and 20 cells per 10 ml of blood (40-80 ϫ 10 6 nucleated cells) has previously been shown to contain 500 atomol EWS-Fli1 copies per g RNA. 23 Since individual RT-PCR determinations were only eligible for final interpretation if parallel analysis of 1 g RNA from each of these dilutions tested positive, the sensitivity for reliable tumour cell detection in our study is defined as at least 2000 copies of chimeric ET RNA per g RNA. Using other cell lines with lower EWS-Fli1 content in sensitivity controls may further decrease the threshold for tumour cell detection by RT-PCR.
In our study, all RT-PCR results were blinded and therefore did not influence the acceptance of a patient for HDC and stem cell reinfusion. Among seven patients in complete clinical remission after HDC, four had received PBPC which tested RT-PCR positive just once. All five patients who progressed after HDC had at least one positive determination in their PBPC product. However, since tumour cell-specific RNA at levels above the threshold of the method was reproducibly detectable only in a single case, no prognostic conclusions can be drawn. The one consistently positive sample and two singly positive apheresis products were derived from patients (Nos 2 and 9) with RT-PCR-negative BM before harvest. This finding may support the concern that tumour cells could be mobilised from the tumour by G-CSF or GM-CSF. Alternatively, BM sampling may have missed focally involved sites.
Despite the high frequency of RT-PCR detectable BM involvement at diagnosis of the high risk ET patients studied, significant tumour cell contamination of PBPC harvests was rarely detectable. This result contrasts with findings in patients with advanced stage neuroblastoma. Miyajima et al 24 found 20% tumour cell contaminated PBPC samples in neuroblastoma patients using the less sensitive tyrosine hydroxylase PCR approach. In their study cohort, 67% of the patients had residual tumour cells in BM before harvest. In contrast, despite the fact that most of the ET patients investigated in our study did not achieve CR before harvest, BM examinations at that time were consistently negative, indicating that ET responds well to chemotherapy. Since even low levels of tumour cell contamination in PBPC below the limits of RT-PCR may be of relevance for relapse after HDC and stem cell reinfusion, purging or selection of CD34 ϩ cells, which potentially reduce tumour cell contamination by at least one log, 14 may still be necessary for most ET patients. To further clarify this question future prospective studies will have to carefully consider the threshold of tumour cell detectability by RT-PCR.
